Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00771615 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 469
- Enrollment target
NCT00771615: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00771615 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 469 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (253% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00771615, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 469 participants
- Enrollment target
Study Summary
The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
Primary Outcome
A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination (Day 0) titer less than (\<) 1:10 for HI and a post-vaccination reciprocal titer greater than or equal to (≥) 1:40, or a pre-vaccination reciprocal titer ≥ 1:10 for HI and at least a 4-fold increase in post-vaccination reciprocal titer.
Interventions
- BIOLOGICAL GSK A/turkey H5N1 Influenza vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2008-10-16 |
| Est. Completion | 2009-12-04 |
| Phase | Phase 2 |
What the finished NCT00771615 record still lists
NCT00771615 is an interventional study that assigns participants to a tested intervention. The registered 469 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (253% higher).
The record links to 0 conditions, and to 1 intervention - of which GSK A/turkey H5N1 Influenza vaccine is the first listed.
NCT00771615 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00771615 about?
NCT00771615 is a clinical study titled "Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years". The purpose of this observer-blind study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic when given to adults aged 18-64 years.
What is the current status of trial NCT00771615?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 469 participants. The study started on 2008-10-16. Estimated completion is 2009-12-04.
What interventions are being tested in trial NCT00771615?
The interventions under investigation include: GSK A/turkey H5N1 Influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00771615?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00771615's enrollment target sits among peer trials
469 80th of 2000 higher than 1,921 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI